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Abstract
Background: Advance directives (AD) may promote preference-concordant care yet are absent in many patients
with Chronic Obstructive Pulmonary Disease (COPD). In order to begin to inform AD discussions between clinicians
and COPD patients, we constructed a decision tree to estimate the impact of alternative AD decisions on both
quality and quantity of life (quality adjusted life years, QALYs).
Methods: Two aspects of the AD were considered, Do Not Intubate (DNI; i.e., no invasive mechanical ventilation)
and Full Code (i.e., may use invasive mechanical ventilation). Model parameters were based on published estimates.
Our model follows hypothetical patients with COPD to evaluate the effect of underlying COPD severity and of
hypothetical patient-specific preferences (about long-term institutionalization and complications from invasive
mechanical ventilation) on the recommended AD.
Results: Our theoretical model recommends endorsing the Full Code advance directive for patients who do not
have strong preferences against having a potential complication from intubation (ETT complications) or being
discharged to a long-term ECF. However, our model recommends endorsing the DNI advance directive for patients
who do have strong preferences against having potential complications of intubation and are were willing to
tradeoff substantial amounts of time alive to avoid ETT complications or permanent institutionalization. Our
theoretical model also recommends endorsing the DNI advance directive for patients who have a higher
probability of having complications from invasive ventilation (ETT).
Conclusions: Our model suggests that AD decisions are sensitive to patient preferences about long-term
institutionalization and potential complications of therapy, particularly in patients with severe COPD. Future work
will elicit actual patient preferences about complications of invasive mechanical ventilation, and incorporate our
model into a clinical decision support to be used for actual COPD patients facing AD decisions.
Background
Advance directives (AD) allow patients to specify prefer-
ences about the care they would receive in the event of
acute illness, and are recommended for comprehensive
medical care [1-3]. However, compliance with AD speci-
f i c a t i o ni s<1 5 %i nt h eg e n e r a lp o p u l a t i o n[ 4 ] .W h i l e
federal policy supports AD [5], it focuses primarily on
the inpatient setting. Lack of AD discussions in the out-
patient setting may postpone the discussion inappropri-
ately to the setting of acute illness, when patients may
be too sick to consider their options carefully [6,7].
Indeed, only 25% of patients have AD at the time end of
l i f ed e c i s i o n sm u s tb em a d e[ 4 ]w h i c hc o u l dl e a dt o
patient dissatisfaction and misguided use of limited
healthcare resources [8-10].
Barriers to discussing AD in the outpatient setting
include both patient and physician discomfort; fear that
the discussion will cause anxiety or take away hope; and
lack of patient-tailored information [11-13]. Lack of tai-
lored information is a particularly important barrier, as
most AD use vague and unintuitive hypothetical scenarios
[14,15], rather than the patient-specific information rele-
vant to individual decision making [16]. Prognostic esti-
mates are more accurate when based on disease-specific
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mation [17].
Chronic Obstructive Pulmonary disease (COPD) is a
progressive illness that exemplifies the need for AD dis-
cussions, as many patients will experience exacerbations
requiring hospital admission. A decision about mechani-
cal ventilation is an important component of AD and
can prepare patients for possible treatment scenarios.
While intubation and other life-saving interventions can
be offered, the outcomes may not always be consistent
with a patient’s preferences. Decision analytic modeling
c a ns y n t h e s i z ee v i d e n c eb a s e dk n o w l e d g et oe s t i m a t e
the outcomes of decisions and provide a recommended
decision but has not been used before to inform the
content of AD. Therefore, we constructed a theoretical
decision analytic model using disease-specific informa-
tion for COPD, to begin to assist COPD patients and
their health care providers in the discussion of AD.
Methods
To inform the AD discussion for COPD patients, we
developed a decision model for advance directives that
could accommodate a wide array of patient preferences.
Decision analytic modeling is used for complex decision
making in which there are competing treatments and
prognoses. Treatment pathways and outcomes are
represented explicitly, often using computer simulation,
with probabilities based on published clinical studies.
The ‘preferred’ or ‘recommended’ decision is that which
maximizes the expected value of the outcome of inter-
est, such as survival, quality of life or cost-effectiveness.
Modeling is used to supplement clinical data in situa-
tions when the influential variables of the decision need
to be discovered and when there is uncertainty about
clinical inputs. A well-designed decision model can
function as a virtual clinical trial, with the benefit of
being able to change all the parameters individually or
simultaneously to test the effect on outcomes and to
discover the most influential variables.
We constructed our decision analytic model with two
alternative decisions for the AD, Do Not Intubate
([DNI] i.e., no invasive mechanical ventilation) and Full
Code (i.e., may use invasive mechanical ventilation if
necessary) in the event of respiratory failure from a
COPD exacerbation. Our outcome of interest was a
combination of survival and quality of life (QALYs). We
focused on COPD exacerbation as the most common
cause of respiratory failure requiring hospitalization in
patients with COPD. We performed analyses for three
scenarios of COPD severity (mild, moderate and severe),
u s i n gG O L Dc r i t e r i a[ 1 8 ] .W et h e nu s e dh y p o t h e t i c a l
patient preferences about discharge location and com-
plications of intubation to evaluate the effect on the
recommended AD.
Model overview
We constructed a decision tree using TreeAge software
(Version 1.0.2, 2009, Williamstown MA) to model the
impact of yearly AD decisions on quality-adjusted life-
years (QALYs). QALYs are a measure of disease burden
that integrates quality with quantity of life.
Model structure
Our model follows hypothetical patients with COPD
who are having annual AD discussions (Figure 1). Treat-
ment pathways specify location of treatment (Intensive
Care Unit [ICU] vs. regular ward) and intensity of treat-
ment (mechanical ventilation invasively with endotra-
cheal tube [ETT] vs. noninvasive mechanical ventilation
[NIMV] vs. medical treatment without mechanical venti-
lation vs. no medical interventions [Comfort Measures
Only, (CMO)]).
Data used in the model
Three types of data are used in the model: transition
probabilities (the probabilities of moving from one
branch of the decision tree to the next branch), utilities
(values placed on being in a given state of health), and
life expectancies (Additional file 1). All data was
extracted from published clinical trials when available.
Transition Probabilities
Probabilities used in the model specify treatment path-
ways (ETT vs. NIMV vs. no mechanical ventilation vs.
CMO), their short term outcomes, and their long-term
outcomes. Data for the probability of ETT was stratified
by severity of respiratory exacerbation (severely ill vs.
moderately ill) and by code status. Severe respiratory
exacerbation (severely ill) was defined as a pH < 7.29,
which was chosen because it was the prevalent threshold
in the literature. We used expert opinion for the prob-
ability of mechanical ventilation for DNI patients as this
data was not available.
“Short term outcomes” were outcomes that occurred
in the hospital, and included successful weaning from
mechanical ventilation, complications of ventilator sup-
port, and death. The literature defines complications
heterogeneously, including the inability to discontinue
mechanical ventilation [19-21] and end organ damage
(e.g., sepsis from ventilator associated pneumonia, renal
failure, septic shock and cardiovascular collapse)
[22-24]. To reduce heterogeneity we defined ETT com-
plications as end organ damage, infection, or the inabil-
ity to discontinue mechanical ventilation. NIMV
complication was defined as the inability to wean from
mechanical ventilation, based on the available literature
[22,23,25-33].
Long-term outcomes of treatment include permanent
institutionalization in an extended care facility (long-term
ECF), temporary institutionalization for rehabilitation
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charge to home, and were dependent on the baseline
severity of COPD exacerbation and preceding short-term
outcomes [21].
Utilities
A utility is a preference-weighted, generic, quality of life
measure on a scale of 0-1. We estimated COPD utilities
based on reported estimates for chronic lung diseases
[34]. We calculated the utility of discharge to long-term
ECF and the utility of ETT complications using time
tradeoff scenarios in which hypothetical patients were
asked how much time in their current state of health
they would tradeoff to avoid 1 month of complications
from intubation [35]. These utilities had negative values
(corresponding to states worse than death) if the patient
was willing to tradeoff large amounts of time alive to
avoid 1 month of intubation and associated
complications.
Life expectancy
We estimated life expectancy (LE) in COPD based on
the BODE index data on COPD survival [36]. The mean
a g ef o rt h ec o h o r tu s e dt od e t e r m i n eC O P Ds u r v i v a l
probabilities was 66, which was similar to the mean age
of 70 for hospitalization for COPD exacerbation [37,38].
We estimated LE in a long-term ECF from a study of
one year mortality in nursing homes, [39] and used the
DEALE (Declining Exponential Approximation of Life
Expectancy) [40], to convert survival probabilities to LE.
Evidence Synthesis
Rather than arbitrarily choosing single studies to inform
parameter estimation, we used decision rules to pool
relevant data: when the data were sufficiently homoge-
n e o u sw ep o o l e dr e s u l t su s i n gt h er a n d o me f f e c t s
method of Der Simonian and Laird. Homogeneity was
defined as having a Q-statistic of > 0.10, an I-statistic of
< 25% and a p-value of < 0.05 with no significant out-
liers on Forest plot. If data were insufficiently homoge-
neous we used the median value as our point estimate
and specified plausible ranges based on the lowest and
highest reported confidence intervals. If insufficient data
was available we used expert opinion and employed a
wide plausible range for sensitivity analyses. Finally,
back calculation was used for some variables using other
parameter estimates in the decision tree.
Figure 1 The advance directives decision model. The square node at the left of the diagram is a “choose” node, representing the choice of
endorsing a DNI vs. Full Code AD. The circles at the origin of each branch are chance nodes, representing events that may or may not happen
with a specified probability. After being admitted to the hospital with an exacerbation patients could be admitted to either the intensive care
unit (ICU) or a regular ward (Ward), with non-ventilatory treatment (no NIMV) only offered on the Ward and ETT only in the ICU. Patients who
failed mechanical ventilation could opt for no further treatment, (Comfort Measures Only; “CMO“). The triangles at the end of each path (the
‘terminal node’) represent the health effects associated with the full sequence of events in the path Paths end in death; discharge to either
extended care facility for a short term or a long-term; or discharge to home. * ECF discharge is either permanent institutionalization in an ECF
(long-term ECF), or temporary institutionalization in an ECF followed by return to home (short-term ECF). Discharge to long-term ECF occurred
only in the pathways where there were complications of mechanical ventilation or in patients who survived CMO.
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One-way sensitivity analysis varies each variable inde-
pendently across a plausible range of values (usually the
95% CI) while keeping all other variables constant to
assess the influence of data uncertainty on the robust-
ness of the model. Model robustness was determined by
whether the recommended AD changed as the para-
meter estimates were varied across their plausible
ranges, and whether the difference in QALYs between
Full Code and DNI changed (eg., whether the difference
in QALYs for DNI vs. Full Code changed when the
lower bound of the 95% CI was used for probability of
ETT complication). For the utility of long-term ECF and
of complications from intubation (ETT complications)
we used the utilities generated from the hypothetical
time tradeoff scenarios.
Results
The recommended AD decision varied substantially with
hypothetical patient preferences. When hypothetical
patients were not willing to tradeoff any time alive to
avoid complications of intubation or long-term institu-
tionalization, a Full Code AD resulted in greater QALYs
than DNI. As patients were willing to tradeoff more
time alive to avoid complications of intubation or long-
term institutionalization, DNI became the recommended
choice, particularly for patients with severe COPD.
Hypothetical patients not willing to tradeoff time alive to
avoid intubation
For hypothetical patients who did not have a strong pre-
ference against complications of intubation (i.e., were
not willing to give up life expectancy to avoid complica-
tions of intubation), Full Code was recommended when
compared to DNI regardless of COPD severity. How-
ever, the strength of the recommendation to be Full
Code decreased as the severity of baseline COPD
increased: for patients with mild COPD the increase in
QALYs for choosing Full Code instead of DNI was 0.74
QALYs, whereas for patients with severe COPD the
increase in QALYs for choosing Full Code instead of
DNI was 0.13 QALYs.
Hypothetical patients willing to tradeoff time alive to
avoid intubation
For hypothetical patients who had a strong preference
against complications of intubation DNI was recom-
mended compared to Full Code, particularly as COPD
severity increased. For patients with mild COPD, DNI
became the recommended directive when a patient
was willing to trade off ≥ 1y e a rt oa v o i d1m o n t ho f
complications of intubation (Figure 2A). For patients
with severe COPD, DNI w a sa l w a y st h er e c o m m e n d e d
AD, unless a patient was only willing to tradeoff
<3 weeks of time alive to avoid 1 month of complica-
tions of intubation and/or willing to tradeoff <2 months
of life expectancy in order to avoid long-term institu-
tionalization (Figure 2C).
Sensitivity Analyses
We varied each input to the model across its plausible
range to determine whether our results were robust (i.e.,
whether the recommended AD changed to Full Code
and whether the difference in QALY changed substan-
tially), (Figures 3A-C). We first limited these analyses to
patients who were unwilling to trade off any time alive
to avoid intubation or long-term institutionalization.
The mild COPD scenario (Figure 3A) yielded the most
robust inferences for decision making. All except one of
the probability ranges included 0, indicating that plausi-
ble range variation rarely changed the recommended
AD. The severe COPD scenario yielded the least robust
inferences for decision making Variables that led to DNI
being favored were an increase in the probability of
ETT complications (≥ 0.617, DNI favored), and a
decrease in the probability of failing NIMV when
severely ill (i.e., higher likelihood of survival with just
NIMV treatment; ≤ 0.14 DNI favored).
Discussion
In this study, we constructed a theoretical decision ana-
lytic model of advance directive choices for COPD
patients in the event of a COPD exacerbation. We
looked at the effect of disease severity and hypothetical
patient preferences on quality adjusted life years and
thus the model’s recommended advance directive. The
variables with greatest influence on quality adjusted life
years were patient preferences regarding permanent
institutionalization and ETT complications as well as
patients’ severity of COPD. Patient preferences were
most influential in patients with severe COPD: when the
utility of long-term ECF was ≤ 0 (i.e., “I think living in a
nursing home permanently is the same as or worse than
being dead”), the recommended directive became DNI.
Other influential variables were the probabilities of ETT
complication and NIMV complication. The recom-
mended directive also changed to DNI when the prob-
ability of ETT complications increased, and when the
probability of NIMV failure decreased (i.e., higher likeli-
hood of survival with just NIMV treatment).
We chose COPD-related respiratory failure in order to
focus on a specific and common scenario requiring deci-
sion making. Using our results a clinician can compare
and contrast prognoses with different AD choices. It is
our hope that this will facilitate clinicians to initiate AD
discussion with their COPD patients, incorporating their
individual preferences (e.g., about long-term institutio-
nalization). Other patient-specific factors, such as
Hajizadeh et al. BMC Medical Informatics and Decision Making 2010, 10:75
http://www.biomedcentral.com/1472-6947/10/75
Page 4 of 8physical and psychiatric comorbidities, prior mechanical
ventilation outcomes, prior admissions, baseline func-
tional status (ADLs) and home support, may influence
the probability of complications and change the recom-
mended AD decision for individual patients, and future
clinical research should explore their relative importance
and their feasibility for incorporation into decision sup-
ports. Future research may also explore further develop-
ing tools to elicit the patient preferences identified by
our model.
Although there was insufficient data to inform esti-
mates for some variables requiring us to rely on a single
study or on expert opinion, the influential variables on
sensitivity analysis were not d e r i v e db ye x p e r to p i n i o n .
The probability of ETT complications, however, was an
influential variable for which only one study was avail-
able [41], because most studies do not distinguish
between mortality from ETT and complications from
ETT that lead to mortality [41]. We have thus identified
an important variable to focus future clinical research in
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Figure 2 Sensitivity Analyses of the utility of discharge to long-term ECF and of the utility of having a complication from intubation.
Results of two way sensitivity analyses are illustrated as tables with increasing willingness to tradeoff time from life expectancy (LE) to avoid
discharge to long-term ECF; and to avoid having complications from intubation. The shaded regions are utilities for which the recommended
directive is DNI. Utilities have negative values (corresponding to states worse than death) if the patient is willing to tradeoff large amounts of
time alive to avoid complications from intubation. The numbers in brackets represent the calculated utilities. Three separate figures correspond
to the effect of preferences on the AD decision for different severities of baseline COPD. For patients with mild COPD (Figure 3a), DNI becomes
the recommended directive only when the patient is willing to tradeoff more than 1 year of LE to avoid complications of intubation. For
patients with moderate COPD (Figure 3c), DNI becomes the recommended directive when the patient is willing to tradeoff more than 6 months
of LE to avoid complications of intubation. DNI also becomes the recommended directive when the patient is willing to tradeoff more than 1
year of LE to avoid long-term ECF. For patients with severe COPD (Figure 3c), DNI becomes the recommended directive when the patient is
willing to tradeoff more than 1 month of LE to avoid complications of intubation. DNI also becomes the recommended directive when the
patient is willing to tradeoff more than 2 months of LE to avoid long-term ECF. When taking both patient preferences into account, if the
patient is willing to tradeoff more than 1 week of LE to avoid complications of intubation and discharge to long-term ECF, DNI becomes the
recommended directive.
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of ETT complications will improve advance directive
decision making by allowing quality of life to be dis-
cussed in the event of survival after intubation. In addi-
tion, the preference-specific variables (e.g., willingness to
trade off time alive to avoid intubation), were not
derived from the literature. We argue that these vari-
ables are more informative if patient-specific rather than
based on cohort studies from the literature. Actual
patient-specific preferences will be obtained in the
future by coupling the model to a decision aid that eli-
cits patient-preferences (e.g., preferences about health
states) and will allow for individually tailored advance
directive recommendations.
Another important limitation of our model is that it
does not use state transitions, and therefore is not able to
assess the influence of multiple respiratory exacerbations
within one year. Patients who have multiple exacerbations
have increasing severity exacerbations and poorer out-
comes than is reflected in the model [42,43]. Additionally,
we assumed that the utility of discharge home after a
COPD exacerbation, and LE, was the same as the utility
and LE before COPD exacerbation. The literature suggests
that some patients who are discharged home do not return
Incremental Change in QALYs, Full Code / Do Not Intubate Advance Directive. 
a.    b.    c. 
Figure 3 Tornado Diagrams. Three separate graphs correspond to the three alternative scenarios for COPD severity in our base case analyses.
(a., Mild COPD; b., Moderate COPD; c., Severe COPD). Results of one way sensitivity analyses are illustrated as tornado diagrams with the
horizontal bars representing the incremental change in QALYs for Full Code compared to DNI advance directive. The widest bars represent the
variables that the model is most sensitive to because changes in their parameter estimates result in large changes in QALY. Variables that cross
the 0 mark indicate a change in the recommended AD from Full Code to DNI. For the mild COPD scenario (Figure 2a), there is no change in the
recommended directive when parameter estimates for the model variables are changed. For the moderate COPD scenario (Figure 2b), DNI
becomes the recommended directive when the probability of having a complication from ETT increases. For the severe COPD scenario (Figure
2c), DNI becomes the recommended directive when the probability of having a complication from ETT increases; and when the probability of
failing NIMV decreases. ETT = Invasive mechanical ventilation via endotracheal intubation; NIMV = Noninvasive mechanical ventilation; ECF =
Extended Care Facility; CMO = Comfort Measures Only; DNI = Do Not Intubate; ICU = Intensive Care Unit.
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Page 6 of 8to normal quality of life immediately, and that health
related quality of life suffers for some time after the acute
symptoms have resolved [43,44]. Future work includes
evolving the decision tree into a Markov state transition
model that can represent the clinical course of severe
COPD with greater fidelity; and incorporating the model
into a decision aid using patient preference to support
shared decision making. Future work may also include
gathering more knowledge about a wide variety of impor-
tant domains, such as the effect of clinician’s specialty on
the AD decisions, the influence of patient-specific factors
such as gender, religion, cultural background, surrogate
involvement and living situation (i.e., what resources the
patient has to assist with home care); and the patient’s
reactions to the model.
Although we believe that informing all COPD patients
about alternate treatment options in the event of severe
respiratory exacerbations, the ideal timing of this discus-
sion needs to be established (e.g., after deterioration in
PFTs are noted in a patient with severe COPD). Appro-
priate psychiatric counseling may also need to be made
available in the event of any distress caused by the dis-
cussion of end of life scenarios, and future work on a
decision aid will assess patient’s reactions to this
discussion.
Conclusions
In summary, our model estimates both the survival from
alternate advance directives as well as the resulting qual-
ity of life based on hypothetical individual patient pre-
ferences. We believe that making our model available to
clinicians in the form of a decision aid, coupled with
actual patient preference elicitation, will better inform
AD shared decision making and is one step towards
increasing preference-congruent care at the end of life.
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